Recombinant Human Urokinase-Type Plasminogen Activator is a potent marker of invasion and metastasis in many human cancers associated with breast, colon, stomach, bladder, brain, ovary and endometrium.
性状 | Solution |
中文名称 | 重组人Urokinase-Type Plasminogen Activator (HEK293, C-6His) |
储存条件 | Store at ≤ -70°C, stable for 6 months after receipt. |
运输方式 | 冰袋运输,根据产品的不同,可能会有相应调整。 |
Recombinant Human Urokinase-Type Plasminogen Activator is a potent marker of invasion and metastasis in many human cancers associated with breast, colon, stomach, bladder, brain, ovary and endometrium. Urokinase-Type Plasminogen Activator specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
Recombinant Human Urokinase-Type Plasminogen Activator/uPA expressed the target gene encoding Ser21-Leu431 with a 6His tag at the C-terminus.
Accession: P00749
Endotoxin < 1 EU/µg
Apparent Molecular Weight: 45-55 KDa, reducing conditions
Supplied as a 0.2 μm filtered solution of 20mM HEPES, 2mM CaCl2, 10% Glycerol, pH 7.4.
This product is shipped on dry ice. Upon receipt, store it immediately at the temperature listed below.
建议您制定动物给药及实验方案时,尽量参考已发表的相关实验文献(溶剂种类及配比众多,简单地溶解目的化合物,并不能解决动物给药依从性、体内生物利用度、组织分布等相关问题,未必能保证目的化合物在动物体内充分发挥生物学效用)。
体内实验的工作液,建议您现用现配,当天使用;如在配制过程中出现沉淀、析出现象,可以通过超声和(或)加热的方式助溶。
切勿一次性将产品全部溶解。
请在下面的计算器中,输入您的动物实验相关数据并点击计算,即可得到该实验的总需药量和工作液终浓度。
例如您给药剂量是10 mg/kg,平均每只动物的体重为20 g,每只动物的给药体积是100 μL,动物数量为20只,则该动物实验的总需药量为4 mg,工作液终浓度为2 mg/mL。
1:鉴于实验过程的损耗,建议您至少多配1-2只动物的量;
2:为该产品最终给药时的浓度。